Prof. Dr. med. et phil. nat. Markus Jörger
chief of service
Medizinische Onkologie und Hämatologie · Dept. I
AMG 355 20220028
Oct 17, 2024Eine Phase-1-Studie am Menschen zur Bewertung der Sicherheit, Verträglichkeit, Pharmakokinetik und Wirksamkeit von AMG 355 als Monotherapie und in Kombination mit Pembrolizumab bei Patienten mit fortgeschrittenen soliden Tumoren
Clinical Studies - Oct 17, 2024 - Dec 31, 2028
Ongoing
Project leader: Jörger Markus
Members: Donno Monica, Müller Fiona
SAKK 66/22 - Invincible 4 SAKK
Oct 17, 2024Protocol SAKK 66/22: Intratumoral INT230-6 followed by neoadjuvant immunochemotherapy in patients with early triple-negative breast cancer (TNBC). An openlabel randomized two-cohort phase 2 clinical trial. INVINCIBLE-4-SAKK
Clinical Studies - Oct 17, 2024 - Dec 31, 2029
Ongoing
Project leader: Jörger Markus
Members: Dei Cas Alissa, Müller Fiona
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08) (Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)
Aug 13, 2024
Clinical Studies - Aug 13, 2024 - Dec 31, 2028
Ongoing
Project leader: Jörger Markus
Members: Harder Anja, Quinter Janine
A first-in-human, open-label, multicenter Phase l/ll study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1)
Jun 13, 2024
Clinical Studies - Jun 13, 2024 - Dec 31, 2028
Ongoing
Project leader: Jörger Markus
Members: Sennhauser Andrina, Müller Fiona
DS1062-A-U303 ( TROPION-lung07) A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations TROPION-Lung07
May 14, 2024
Clinical Studies - May 14, 2024 - Dec 31, 2028
Ongoing
Project leader: Jörger Markus
Members: Harder Anja, Quinter Janine
A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer.
Dec 21, 2023
Clinical Studies - Dec 21, 2023 - Dec 31, 2027
Ongoing
Project leader: Jörger Markus
Members: Quinter Janine, Radovanovic Suzana
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Oct 30, 2023
Clinical Studies - Oct 30, 2023 - Dec 31, 2026
Ongoing
Project leader: Jörger Markus
Members: Bürki Ramona, Quinter Janine
A Phase 1/2 Study of BMS-986408 Alone and in Combination with Nivolumab or with Nivolumab and Ipilimumab in Participants with Advanced Solid Tumors
Jun 21, 2023Das primäre Ziel dieser Studie ist die Charakterisierung des Sicherheitsprofils von BMS-986408 als Monotherapie und in Kombination mit Nivolumab oder Nivolumab und Ipilimumab, um die maximal verträgliche Dosis (MTD) zu ermitteln. Außerdem soll die em...
Clinical Studies - Jun 21, 2023 - Dec 31, 2030
Ongoing
Project leader: Jörger Markus
Members: Hutter Franziska
A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors
Jan 11, 2023Die Studie untersucht die Sicherheit, Verträglichkeit, Pharmakokinetik und Wirkung von MK-0472 alleine und kombiniert mit Pembrolizumab. «Pharmakokinetik» bedeutet unter anderem die Aufnahme, Verarbeitung und Abbau der Substanz im Körper. Es werden v...
Clinical Studies - Jan 11, 2023 - Dec 31, 2028
Ongoing
Project leader: Jörger Markus
Members: Donno Monica, Quinter Janine
IP-001_RFA (IP-IIO-622): Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter Phase 1b/2a trial in colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma patients
Nov 8, 2022Diese Studie untersucht die Sicherheit und erste Wirksamkeit einer immunstimulierenden thermischen Ablation in Kombination mit dem Prüfpräparat IP-001, welches nach der Ablation in den Tumor injiziert wird (intratumoral). Die thermische Ablation ist...
Clinical Studies - Nov 8, 2022 - Dec 31, 2024
Completed
Project leader: Jörger Markus
Members: Wittwer Yvonne, Quinter Janine
CATALYM CTL-002-001 A PHASE 1/2, FIRST-IN-HUMAN, TWO-PART, OPEN-LABEL CLINICAL TRIAL OF INTRAVENOUS ADMINISTRATION OF CTL-002 GIVEN AS MONOTHERAPY AND/OR IN COMBINATION WITH AN ANTI-PD-1 CHECKPOINT INHIBITOR IN SUBJECTS WITH ADVANCED-STAGE, RELAPSED/REFRACTORY SOLID TUMORS
Sep 2, 2022Diese klinische Studie wird durchgeführt, um ein neues Prüfpräparat mit der Bezeichnung "CTL-002" zu testen. CTL-002 gehört zu einer Klasse von Medikamenten, die als monoklonale Antikörper bezeichnet werden. Antikörper sind vom Immunsystem hergestell...
Clinical Studies - Sep 2, 2022 - Sep 8, 2030
Completed
Project leader: Jörger Markus
Members: Bürki Ramona, Quinter Janine
ANV419 Single Agent (Parts A-C) or Combination (Part D) First in Human Study Phase 1/2: Open-label, Dose Escalation and Expansion Study in Patients with Relapsed/Refractory Advanced Solid Tumors and Multiple Myeloma. (Anaveon)
Mar 3, 2022Diese klinische Studie wird durchgeführt, um ein neues Arzneimittel mit dem Namen ANV419 zu testen. Dieses neue Arzneimittel hat im menschlichen Körper eine Wirkung ähnlich Interleukin-2. Diese klinische Studie wird durchgeführt, um die Sicherheit...
Clinical Studies - Mar 3, 2022 - Mar 2, 2024
Automatically Closed
Project leader: Jörger Markus
Members: Wittwer Yvonne, Quinter Janine
A multicenter, non-randomized, open-label phase 1b study to determine the maximum tolerated and recommended phase 2 dose of the ATR Inhibitor BAY 1895344 in combination with pembrolizumab and characterize its safety, tolerability, pharmacokinetics and preliminiary anti-tumor activity in patients with advanced solid tumors
Apr 14, 2021BAY-1895344 und Pembrolizumab bei ausgewählten Tumoren mit genetischen Alterationen von ATM.
Clinical Studies - Apr 14, 2021 - Feb 21, 2022
Automatically Closed
Project leader: Jörger Markus
ON-TRK: PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib
Apr 14, 2021TRK fusion cancer is rare but presents as a variety of solid tumors. Larotrectinib is a highly selective TRK inhibitor that, in a pooled analysis of patients in phase 1/2 clinical trials, demonstrated an effective and sustained response in the ma...
Clinical Studies - Apr 14, 2021 - Dec 31, 2025
Completed
Project leader: Jörger Markus
Members: Kern Julia, Quinter Janine
SAKK 17/18 Origin
Mar 5, 2021A significant number of patients with malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) are not cured with available treatments and will eventually relapse. After relapse treatment options are limited. Preclinical in vitro s...
Clinical Studies - Mar 5, 2021 - Dec 12, 2024
Automatically Closed
Project leader: Jörger Markus
Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter phase Ib/IIa trial with expansion cohorts in melanoma and soft tissue sarcoma patients
Oct 7, 2020Diese Studie untersucht die Sicherheit und erste Wirksamkeit einer immunstimulierenden intratumoralen Laser-Wärmetherapie in Kombination mit dem Studienmedikament IP-001, welches in den Tumor injiziert wird. Alle Patienten in dieser Studie erhalten d...
Clinical Studies - Oct 7, 2020 - Dec 31, 2024
Ongoing
Project leader: Jörger Markus
Members: Wittwer Yvonne, Quinter Janine
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembroli-zumab for First-Line Treatment of PD-L1 Positive Recur-rent/Metastatic Head and Neck Squamous Cell Carcinoma
Jul 10, 2020The study will evaluate the efficacy of GSK3359609 in combination with pembrolizumab compared with pem-brolizumab plus placebo as a standard first-line chemo-therapy-free regimen in HNSCC. All participants will be stratified by 2 factors i) PD-L1 CPS...
Clinical Studies - Jul 10, 2020 - Jul 31, 2021
Automatically Closed
Project leader: Jörger Markus
Predictive markers for checkpoint-based immunotherapy in advanced non-small cell lung cancer
Jan 1, 2020The aim of this study is to elucidate a novel biomarker constellation with superior predictive value for PD-1/PD-L1-targeted immunotherapy in advanced non-small cell lung cancer.
Fundamental Research - Jan 1, 2020 - Dec 31, 2021
Completed
Project leader: Bösch Maximilian
Members: Baty Florent, Brutsche Martin, Früh Martin, Jörger Markus
A phase I/Ib, open-label, multi-center dose escalation study of NIS793 in combination with PDR001 in adult patients with advanced malignancies (CNIS793X2101)
Sep 9, 2019This is a first-in-human (FIH), open label, phase I/Ib, multi-center study which consists of: - a dose escalation part of NIS793 as single agent and in combination with PDR001. Patients treated with NIS793 single agent will switch to NIS793 in combin...
Clinical Studies - Sep 9, 2019 - Jul 1, 2021
Automatically Closed
Project leader: Jörger Markus
Open label, non-randomized, Phase IB study to characterize safety, tolerability and recommended dose of EDO-S101, a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic melanoma
May 2, 2019Neuere Immuntherapien zur Behandlung des fortgeschrit-tenen, metastasierten Melanoms haben zu einer Verbes-serung des Gesamtüberlebens geführt. Diese Immuntherapien führen zu einer Verstärkung der natürlichen Krebsabwehr durch das Immunsystem. Einige...
Clinical Studies - May 2, 2019 - Dec 17, 2023
Automatically Closed
Project leader: Jörger Markus